At the 2025 World Conference on Lung Cancer in Barcelona, the 23andMe Research Institute, in collaboration with Troper Wojcicki Philanthropies and the health data software company Lifebit, introduced ...

Through our research data strategy, we aim to improve how we use research data to answer important questions that lead to better patient outcomes.

Deep Learning–Based Body Composition Analysis for Outcome Prediction in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Insights From the LOTIS-2 Trial Over the past 50 years, multiple pathology ...

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab The prognostic model demonstrated ...

Forty-five years after Terry Fox set out on his Marathon of Hope, his legacy continues to shape how cancer is studied and treated in Canada. That vision now drives the Marathon of Hope Cancer Centres ...

In an effort to foster progress in cancer research, the National Institute of Standards and Technology (NIST) is releasing detailed and comprehensive data about the entire genetic content of a ...

Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endometrial cancer. The biotech reported a 50% unconfirmed response rate, beating the expectations of William Blair ...

Jeff Leek, PhD, vice president and chief data officer at Seattle-based Fred Hutchinson Cancer Center, was named to the 2025 Time100 AI list for his role in launching the Cancer AI Alliance. The ...

Revolution Medicines, Inc. shares surged on strong Phase 1 data for daraxonrasib in metastatic pancreatic cancer. Click here ...

IDEAYA Biosciences is well-capitalized, with a cash runway into 2029 and multiple upcoming catalysts. Click here to find out ...